Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnded earlyNCT01990261
What this trial is testing

Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 33
Not applicableStudy completedNCT02047903
What this trial is testing

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 161
Testing effectiveness (Phase 2)Active Not RecruitingNCT05526755
What this trial is testing

5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Who this might be right for
Stage II-IIIB Non-small Cell Lung Carcinoma
AstraZeneca 188
Testing effectiveness (Phase 2)Looking for participantsNCT05379803
What this trial is testing

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Who this might be right for
Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 40
Early research (Phase 1)UnknownNCT06362980
What this trial is testing

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Who this might be right for
NSCLC
National Cancer Center, China 20
Testing effectiveness (Phase 2)Looking for participantsNCT07070440
What this trial is testing

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Who this might be right for
Non Small Cell Lung Cancer
Dizal Pharmaceuticals 180
Large-scale testing (Phase 3)Ended earlyNCT02893332
What this trial is testing

Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)

Who this might be right for
Stage IV EGFR Mutated Non-Small Cell Lung Cancer
Sichuan Provincial People's Hospital 200
Not applicableStudy completedNCT04206787
What this trial is testing

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-squamous, Non-Small Cell Lung Cancer
Boehringer Ingelheim 72
Early research (Phase 1)Ended earlyNCT03418532
What this trial is testing

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

Who this might be right for
EGFR-mutated NSCLC (Disorder)
Molecular Partners AG 8
Early research (Phase 1)Study completedNCT00895687
What this trial is testing

Study of Erlotinib in Combination With Bortezomib

Who this might be right for
Advanced Cancer
M.D. Anderson Cancer Center 24
Testing effectiveness (Phase 2)Looking for participantsNCT06755684
What this trial is testing

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Who this might be right for
EGFRNon-Small Cell Lung CancerLocally Advanced Non-Small Cell Lung Cancer+5 more
Peng Zhang 60
Not applicableUnknownNCT06174857
What this trial is testing

Efficacy of Osimertinib in Patients With Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05078931
What this trial is testing

Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Who this might be right for
NSCLC
Shanghai Chest Hospital 35
Post-approval studies (Phase 4)Study completedNCT03853551
What this trial is testing

Osimertinib Study in Indian Patients

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Large-scale testing (Phase 3)Active Not RecruitingNCT06305754
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 550
Testing effectiveness (Phase 2)Active Not RecruitingNCT05712902
What this trial is testing

Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

Who this might be right for
Non-Small Cell Lung Cancer
Dizal Pharmaceuticals 104
Large-scale testing (Phase 3)Looking for participantsNCT07738172
What this trial is testing

Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Neoplasms, Non-Small Cell Lung Cancer
National Taiwan University Hospital 154
Testing effectiveness (Phase 2)Ended earlyNCT03499353
What this trial is testing

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Who this might be right for
Early Breast Cancer
Pfizer 61
Testing effectiveness (Phase 2)Looking for participantsNCT07659795
What this trial is testing

VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

Who this might be right for
Colorectal Cancer
Verastem, Inc. 150
Large-scale testing (Phase 3)Active Not RecruitingNCT05870319
What this trial is testing

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Next Page